vinflunine and Hematologic-Diseases

vinflunine has been researched along with Hematologic-Diseases* in 1 studies

Trials

1 trial(s) available for vinflunine and Hematologic-Diseases

ArticleYear
Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:12

    This phase II study evaluated vinflunine in chemotherapy naive patients with metastatic melanoma. Vinflunine was administered at 350 mg/m(2) every 3 weeks, but after 9 patients this was reduced to 320 mg/m(2) based on interim analyses of all phase II trials. A partial response was observed in 1 of the first 9 patients (11.1%) treated at 350 mg/m(2), which gives a 3.0% [95% confidence interval (CI): 0.08-15.8] response rate in 33 patients. No change was the best response in 13 patients (39.4%) with progressive disease in 16 (48.5%) and 3 were not evaluable for response. The time to response was 1.4 months and duration was 6 months. At 350 mg/m(2) grade 4 neutropaenia occurred in 3 patients (33.3%) and grade 3 in 2 patients (22.2%) while at 320 mg/m(2) grade 4 neutropaenia occurred in 6 patients (25%) and grade 3 in 3 patients (12.5%) with 2 episodes of grade 3 febrile neutropaenia. Two patients (8.3%) had grade 3 anaemia. These results do not show activity at this dose and schedule for vinflunine in patients with chemotherapy naive metastatic melanoma.

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Melanoma; Middle Aged; Skin Neoplasms; Survival Analysis; Treatment Outcome; Vinblastine

2007